Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 09, 2021

SELL
$10.18 - $26.64 $1.92 Million - $5.03 Million
-188,818 Closed
0 $0
Q2 2021

Aug 16, 2021

SELL
$18.57 - $35.68 $4.18 Million - $8.02 Million
-224,838 Reduced 54.35%
188,818 $5.03 Million
Q1 2021

May 14, 2021

SELL
$31.0 - $55.72 $3.63 Million - $6.52 Million
-117,098 Reduced 22.06%
413,656 $14.4 Million
Q4 2020

Feb 08, 2021

SELL
$37.09 - $48.97 $2.59 Million - $3.42 Million
-69,793 Reduced 11.62%
530,754 $19.7 Million
Q3 2020

Nov 09, 2020

SELL
$40.47 - $45.5 $2.65 Million - $2.98 Million
-65,572 Reduced 9.84%
600,547 $24.7 Million
Q2 2020

Aug 10, 2020

BUY
$32.57 - $42.83 $17.4 Million - $22.9 Million
534,092 Added 404.53%
666,119 $27 Million
Q1 2020

May 14, 2020

SELL
$23.3 - $45.96 $668,127 - $1.32 Million
-28,675 Reduced 17.84%
132,027 $4.59 Million
Q4 2019

Feb 12, 2020

BUY
$34.58 - $48.06 $547,574 - $761,030
15,835 Added 10.93%
160,702 $6.89 Million
Q3 2019

Nov 08, 2019

SELL
$36.98 - $48.45 $63,383 - $83,043
-1,714 Reduced 1.17%
144,867 $5.36 Million
Q2 2019

Jul 25, 2019

BUY
$35.13 - $55.53 $309,038 - $488,497
8,797 Added 6.38%
146,581 $6.62 Million
Q1 2019

May 08, 2019

SELL
$42.83 - $59.91 $707,637 - $989,833
-16,522 Reduced 10.71%
137,784 $7.49 Million
Q4 2018

Feb 05, 2019

BUY
$37.97 - $60.16 $330,794 - $524,113
8,712 Added 5.98%
154,306 $7.14 Million
Q3 2018

Nov 13, 2018

SELL
$56.3 - $67.25 $205,213 - $245,126
-3,645 Reduced 2.44%
145,594 $8.85 Million
Q2 2018

Aug 07, 2018

BUY
$44.9 - $64.95 $60,570 - $87,617
1,349 Added 0.91%
149,239 $9.34 Million
Q1 2018

May 08, 2018

SELL
$45.35 - $61.65 $270,558 - $367,803
-5,966 Reduced 3.88%
147,890 $6.83 Million
Q4 2017

Feb 12, 2018

SELL
$41.95 - $60.1 $815,424 - $1.17 Million
-19,438 Reduced 11.22%
153,856 $7.29 Million
Q3 2017

Nov 08, 2017

BUY
$33.4 - $53.9 $5.79 Million - $9.34 Million
173,294
173,294 $9.32 Million

Others Institutions Holding FGEN

About FIBROGEN INC


  • Ticker FGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 93,741,200
  • Market Cap $45M
  • Description
  • FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...
More about FGEN
Track This Portfolio

Track Rothschild & CO Asset Management Us Inc. Portfolio

Follow Rothschild & CO Asset Management Us Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rothschild & CO Asset Management Us Inc., based on Form 13F filings with the SEC.

News

Stay updated on Rothschild & CO Asset Management Us Inc. with notifications on news.